Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney).

NCT06534723 is registered in ClinicalTrials.gov with Sichuan Jishengtang Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06534723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06534723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney).
Lead sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
August 20, 2024
Completion date
December 1, 2026
Enrollment
570 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's dementia